RT Journal Article
T1 Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register.
A1 Vela, Paloma
A1 Sanchez-Piedra, Carlos
A1 Perez-Garcia, Carolina
A1 Castro-Villegas, María C
A1 Freire, Mercedes
A1 Mateo, Lourdes
A1 Díaz-Torné, Cesar
A1 Bohorquez, Cristina
A1 Blanco-Madrigal, Juan M
A1 Ros-Vilamajo, Inmaculada
A1 Gómez, Silvia
A1 Caño, Rocio
A1 Sánchez-Alonso, Fernando
A1 Díaz-González, Federico
A1 Gómez-Reino, Juan J
K1 Ankylosing spondylitis
K1 Biologics
K1 Elderly-onset rheumatoid arthritis
K1 Psoriatic arthritis
K1 Rheumatoid arthritis
AB To assess whether age, at the beginning of biologic treatment, is associated with the time a first adverse event (AE) appears in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), or psoriatic arthritis (PsA). All patients in the BIOBADASER registry diagnosed with RA, AS, and PsA, and classified as young ( 75 years old) at start of biological treatment were included. Factors associated with the appearance of a first AE using adjusted incidence rate ratios (IRR) (Poisson regression) were analyzed. Survival to first AE was studied by Kaplan-Meier analysis and hazard ratios (HR) by Cox regression. 2483 patients were included: 1126 RA, 680 PsA, and 677 AS. Age group stratification was as follows: 63 young, 2127 adults, 237 elderly, and 56 very elderly. Regression model revealed an increased probability of suffering a first AE at age 65 years or older [IRR elderly: 1.42 (CI95% 1.13-1.77)]. Other characteristics associated with AE were female gender, the use of DMARDs, including methotrexate, the presence of comorbidities, and the time of disease duration. Factors that had the greatest impact on survival over a first AE were age > 75 years [HR 1.50 (1.01-2.24)] and female gender [HR 1.42 (1.22-1.64)]. Age at the start of treatment and female gender are key factors associated with the appearance of a first AE with biologics. Other factors related to patient status and treatment were also associated with a first AE in rheumatic patients treated with biologics.
YR 2020
FD 2020-06-15
LK http://hdl.handle.net/10668/15740
UL http://hdl.handle.net/10668/15740
LA en
DS RISalud
RD Apr 17, 2025